Case: Integra LifeSciences Holdings Corporation

Attorneys: Pamela A. Mayer

January 6, 2012 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Plainsboro, New Jersey-based Integra LifeSciences Holdings Corporation (“Integra” or “Company”) (Nasdaq: IART) for potential violations of the federal securities laws. Investors who purchased Integra’s common stock since June 2009 may be affected.

On January 6, 2012, Integra filed a Form 8-K with the SEC disclosing the receipt of an FDA warning letter dated December 21, 2011. The warning letter relates to quality sytems and compliance issues at Integra’s collagen manufacturing facility located in Plainsboro, New Jersey. Among other things, the FDA warning letter says it observed a “failure to establish and maintain adequate procedures to control environmental conditions where environmental conditions could reasonably be expected to have an adverse effect on product quality.” For example, the letter refers to the identification of mold at the manufacturing facility in June 2009 and says that “in spite of [a third party report], your firm …determined that the building was of suitable design to perform operations.”

On January 6, 2012, Integra’s common stock price declined by $6 per share, or 18%, to close at $24.50 per share.

If you purchased Integra’s common stock and would like to discuss our investigation, please e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it .